Yahoo Malaysia Web Search

Sign In

Search results

  1. en.wikipedia.org › wiki › Juno_TherapeuticsJuno Therapeutics - Wikipedia

    Juno Therapeutics Inc was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute.

  2. www.geekwire.com › 2022 › junos-lasting-legacy-how-Juno's lasting legacy: How the cell therapy juggernaut influenced...

    Feb 8, 2022 · When Juno Therapeutics launched in 2013, cell therapy was a nascent field. Early clinical studies were showing dramatic rates of remissions in leukemia patients treated with their own immune...

  3. www.linkedin.com › company › juno-therapeuticsJuno Therapeutics, Inc. | LinkedIn

    Juno Therapeutics, Inc. | 27,610 followers on LinkedIn. We have merged with Bristol Myers Squibb creating a leading biopharma company, ideally positioned to discover, develop and deliver...

  4. www.crunchbase.com › organization › juno-therapeuticsJuno Therapeutics - Crunchbase Company Profile & Funding

    Details. Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies.

  5. www.fiercebiotech.com › biotech › celgene-confirms-9bn-junoCelgene confirms $9B Juno buyout, sees $3B sales for JCAR017

    Jan 22, 2018 · Celgene has agreed to buy CAR-T specialist Juno Therapeutics for around $9 billion in a deal that instantly makes it a big cheese in this emerging therapeutic category.

  6. www.fda.gov › drugs › resources-information-approved-drugsFDA approves lisocabtagene maraleucel for relapsed or refractory...

    May 30, 2024 · On May 30, 2024, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adult patients with relapsed or refractory mantle cell lymphoma (MCL)...

  7. www.celgene.com › newsroom › cellular-immunotherapiesCelgene Corporation to Acquire Juno Therapeutics, Inc.

    Jan 22, 2018 · JCARH125 will enhance Celgene’s campaign against BCMA (B-cell maturation antigen), a key target in multiple myeloma. Additional cellular therapy assets in proof-of-concept trials for hematologic malignancies and solid tumors will add to Celgene’s existing pipeline.